{
	"categories": {
		"data": [
			"18-Q1",
			"18-Q2",
			"18-Q3",
			"18-Q4",
			"19-Q1",
			"19-Q2",
			"19-Q3",
			"19-Q4"
		],
		"title": "Quarter"
	},
	"yaxis": "",
	"tickAmount":5,
	"mintick":0,
	"maxtick":30,
	"series": [
		{
			"name": "Drug A1",
			"data": [
				11,
				14,
				17,
				18,
				21,
				24,
				29,
				30
			]
		},
		{
			"name": "Drug A2",
			"data": [
				0,
				0,
				0,
				17,
				17,
				17,
				18,
				18
			]
		},
		{
			"name": "Drug A3",
			"data": [
				26,
				27,
				28,
				28,
				27,
				27,
				26,
				25
			]
		},
		{
			"name": "Drug A4",
			"data": [
				11,
				11,
				12,
				12,
				11,
				11,
				11,
				11
			]
		}
	],
	"keyinsights": [
		{
			"trend": "down",
			"text": "For Drug A, the effective rebate  has increased by 19% in 2019 Q4 due to  Access Price Group % change  from 6.25% to 7.95% in 2018 Q1"
		},
		{
			"trend": "up",
			"text": "For Drug A2,  Gross sales has increased from 10% to 12% resulting in reduction of effective rebate by 2%"
		},
		{
			"trend": "down",
			"text": "For Drug A, the effective rebate by Payer 1 has increased by 19% due change in Formulary position from P -> P to P->E at the end of 17-Q4"
		},
		{
			"trend": "up",
			"text": "For Drug A1, due to increased competition from Drug K in 18-Q3, ,a 1.2% higher Admin Fees and 1.0% higher Base Rebates , increased the effective rebate % by 2.2%"
		}
	]
}